



ALCORE: Integrative Therapy for Alcohol Use Disorder (AUD)

Dual PPARα and VR1 modulators that regulate reward and satiety mechanisms, control lipid metabolism, and treat steatohepatitis.



Unmet Medical Need

Currently approved treatments (naltrexone, acamprosate) exhibit clinical efficacy rates below 50% and high treatment dropout rates.

High rate of clinical relapse triggered by prior abstinence periods, stress, or contextual/environmental cues.

Lack of targeted oral therapies capable of reducing compulsive alcohol seeking without altering overall caloric intake.

Prevalence & Market Opportunity

Prevalence	Market	Another fact
Worldwide: >100M people affected. >3M annual deaths. In Spain: 3.6% of adult population (6.47% in males). 32% high-risk consumption among youth.	~\$1.5B Global AUD Market ~\$2.5B Global ASH Market >\$25B NASH/Fatty Liver Market	Harmful alcohol use accounts for 5.1% of the global disease burden and generates socioeconomic costs exceeding 2% of GDP in developed countries.

Technology

A novel family of lipid sulfamide derivatives (led by N-oleyl sulfamide, NOS) active via both oral and parenteral routes.

Innovative mechanism of action based on the **dual modulation** of the metabolic receptor PPARα and the sensory target VR1 (TRPV1).

Demonstrated **synergistic effect** when combined with opioid antagonists (nalmefene/naltrexone) and compatibility with GLP-1 receptor agonists.

Results & Proof of Concept

- Significant reduction in self-administration and voluntary alcohol consumption *in vivo* (Wistar rats).
- Substantial inhibition of compulsive consumption and effective prevention of both abstinence-induced and context-induced relapse.
- Target validation via specific receptor blockade with capsazepine (VR1 antagonist) and proven synergy with nalmefene.

Roadmap

IBIMA BIONAND platform is looking for investors to set up a spin-off for the development of the technology.



Patent:

Patent Application: P202430833
Priority: 10/15/2024



Team: Neuropsychopharmacology Research Group

PI: Dr. Fernando Rodríguez de Fonseca

Contact: Innovation and Technology Transfer Unit of IBIMA BIONAND Platform
✉ transferencia@ibima.eu ☎ 952 36 76 00 @ www.ibima.eu